Show simple item record

Files in this item

Thumbnail

Item metadata

dc.contributor.advisorBrown, Verity Joy
dc.contributor.advisorLambert, Jeremy J.
dc.contributor.authorBrazaitis, Casmira T.
dc.coverage.spatialxvii, 207 p.en_US
dc.date.accessioned2017-03-20T12:09:20Z
dc.date.available2017-03-20T12:09:20Z
dc.date.issued2017-06-20
dc.identifieruk.bl.ethos.707267
dc.identifier.urihttps://hdl.handle.net/10023/10495
dc.description.abstractDysfunction of the N-methyl-D-aspartate (NMDA) receptor is thought to contribute to the cognitive deficits of many neurodegenerative diseases and psychiatric disorders. Cognitive symptoms of Alzheimer’s disease can be treated with NMDA receptor antagonists or drugs targeting the cholinergic system; however, there are no effective treatments for cognitive deficits of schizophrenia or Huntington’s disease. With the discovery of a potent and selective allosteric modulator of the NMDA receptor, there is the possibility of new treatments based on NMDA receptor functional-enhancement through neuroactive steroids, closely related in structure to the endogenous neurosteroid, cerebrosterol. The aim of this thesis was to examine steroidal modulation of the NMDA receptor both in vitro and in vivo. In chapter 2, NMDA receptor enhancement of both the synthetic and endogenous neuroactive steroids was assessed in neurons maintained in cell culture using calcium imaging techniques. Sulphation of the steroids greatly increased the efficacy of NMDA receptor enhancement compared to the unsulphated steroids. Chapters 3 and 4 investigate the potential for neuroactive steroids to treat cognitive impairments of Huntington’s disease. Using a mouse model, tests were selected that were analogous to those in which patients are impaired; however, no impairments were found in the mouse model. Chapter 5, therefore, used a different model of cognitive impairment – namely, rats with a set-shifting impairment, as is seen in many psychiatric and neurological disorders, including Huntington’s disease – to assess the effect of the synthetic steroid administration. Unfortunately, the rats did not show the expected impairment. The lack of reliable animal models compromised testing the efficacy of these promising NMDA receptor positive allosteric modulators. Nevertheless, the promising in vitro results suggest that there could still be therapeutic potential. In addition, the compound is a useful research tool for exploring NMDA receptor function in health and disease.en_US
dc.description.sponsorshipThesis funded by MSD Scottish Life Sciences Fund and the Scottish Universities Life Allianceen
dc.language.isoenen_US
dc.publisherUniversity of St Andrews
dc.subjectNMDA receptoren_US
dc.subjectCognitionen_US
dc.subjectPositive allosteric modulationen_US
dc.subjectHuntington's diseaseen_US
dc.subjectCerebrosterolen_US
dc.subject24S-hydroxycholesterolen_US
dc.subject.lccQP364.7B82
dc.subject.lcshMethyl aspartate--Receptorsen
dc.subject.lcshMethyl aspartate--Receptors--Antagonistsen
dc.subject.lcshHuntington's disease--Treatmenten
dc.subject.lcshAllosteric regulationen
dc.titleIn vivo and in vitro studies of positive allosteric modulation of the NMDA receptoren_US
dc.typeThesisen_US
dc.contributor.sponsorMerck Sharp & Dohme. Scottish Life Sciences Funden_US
dc.contributor.sponsorScottish Universities Life Sciences Alliance (SULSA)en_US
dc.type.qualificationlevelDoctoralen_US
dc.type.qualificationnamePhD Doctor of Philosophyen_US
dc.publisher.institutionThe University of St Andrewsen_US


This item appears in the following Collection(s)

Show simple item record